A multicenter Chinese study shows that a machine-learning radiomics model built from routine non-contrast CT scans, combined ...
A small observational study found that serum CXCL-10 and CTLA-4 were associated with HBV viral load and histological ...
An AI model combining ctDNA methylation and clinical data achieved an AUC of 0.903 for detecting liver cancer in patients ...
Four approved PrEP options now span daily pills and long-acting injections. The faculty review how each agent works and where ...
Welltica+ on MSN
Your child’s hepatitis B risk could jump sharply if vaccine timing changes go through
A new US model took a hard look at what happens when the newborn shot is pushed back or left up to parents.
For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
Infants are particularly vulnerable to hepatitis B.
A new study projects that delaying or omitting the hepatitis B shot at birth could increase chronic infections among children by 83%. Under the direction of Health Secretary RFK Jr., the CDC ended its ...
Delaying the newborn hepatitis B vaccine by even a couple of months would have detrimental effects at a population level, new ...
Ending routine vaccination for hepatitis B at birth, as the health secretary has recommended, would increase the number of ...
2don MSN
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Oct 20 (Reuters) - The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B drug Hibsago, allowing patients with the liver infection a way to keep the virus under control after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results